Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Read Full Text


Download PDF


View Table of Contents

Antibodies to Viral Citrullinated Peptide in Rheumatoid Arthritis

CONSUELO ANZILOTTI, GIUSEPPINA MERLINI, FEDERICO PRATESI, CRISTINA TOMMASI, DANIELE CHIMENTI, and PAOLA MIGLIORINI

ABSTRACT.

Objective.
To analyze the frequency of anti-viral citrullinated peptide (anti-VCP) antibodies in sera from patients with rheumatoid arthritis (RA) by an Epstein-Barr virus (EBV)-derived peptide in which arginine is replaced with citrulline.

Methods. Anti-VCP antibodies were determined in 627 serum samples, 300 from patients with RA and 327 from controls, including connective tissue diseases, chronic arthritides, and healthy donors. Among patients with RA, a possible correlation with systemic involvement, disease severity, and disease activity was investigated; in 94 RA patients antibodies to cyclic citrullinated protein (anti-CCP) were also measured.

Results. Anti-VCP antibodies were found in 45% of RA sera versus less than 5% of controls; anti-VCP levels correlated with anti-CCP levels (p < 0.0001), rheumatoid factor (p = 0.02), and erythrocyte sedimentation rate (p = 0.0058). No correlation was found with extraarticular manifestations of the disease or with disease severity.

Conclusion. Anti-VCP antibodies are helpful in discriminating RA from other chronic arthritides or connective tissue disorders. The level of positivity is positively correlated with the anti-CCP level, suggesting that VCP can be considered a novel substrate to detect anti-citrullinated peptide/protein antibodies (ACPA). The reactivity of RA-specific antibodies with a viral citrullinated antigen raises questions on the role of EBV in the induction of ACPA. (First Release Mar 1, 2006; J Rheumatol 2006;33:647-51)

 

Key Indexing Terms:

ANTI-CITRULLINATED PEPTIDE/PROTEIN ANTIBODIES
RHEUMATOID ARTHRITIS

CITRULLINATED PEPTIDES
EPSTEIN-BARR VIRUS


From the Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy.

C. Anzilotti, MD; G. Merlini, MD; Federico Pratesi, BSc; C. Tommasi, MD; D. Chimenti, BSc; P. Migliorini, MD.

Address reprint requests to Dr. P. Migliorini, Clinical Immunology Unit, Department of Internal Medicine, Via Roma 67, 56126 Pisa, Italy. E-mail: p.migliorini@med.unipi.it

Accepted for publication December 7, 2005.


Return to April 2006 Table of Contents



© 2006. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.